← Quality Momentum
QM · rank #4 · 2026-05-13
ARWR
NASDAQ · $10.24B
verdict · CAUTION
Why this pick · factor scores
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +441.05% |
| ROE TTM Return on equity, trailing 12 months. | +75.5% |
| Profit margin Net profit margin, trailing 12 months. | +18.5% |
| Market cap Size filter: > $500M required. | $10.24B |
| Anchor (recent) Close on 2026-04-13 | $63.79 |
| Anchor (far) Close on 2025-04-11 | $11.79 |
AI research card
Independent qualitative review before order placement.
Summary
Arrowhead Pharmaceuticals develops RNA interference-based therapeutics for various diseases.
Rationale
Strong ROE and profit margin combined with positive 12-month momentum suggest a quality company with upward price pressure.
Material risks
- 1Clinical trial failures or regulatory setbacks for key drug candidates.
- 2High valuation relative to current profitability and dependence on future pipeline success.
Verdict reasoning
Pipeline risk and valuation warrant careful monitoring despite strong quant signals.